Hello.
Can you hear me?
Questions across 2 calls
Pritesh Chheda
Firm not listed in source transcripts
GlaxoSmithKline Pharmaceuticals Limited
Yes, I wanted to ask you on the margin side. So, you know, we see a newer margin in quarter four now at about 34%. And last full year, we have gone through a large round of margin upgrade via the SGA line leverage. Any comments on the incremental margin expansion possibility over the full year of 31% which you reported? And obviously, last year, there were fallouts by the management on the reasons for the margin upgrade. So, should 34% exit is a reference one can refer to, or you have any other comments on the margin upside?
Okay. My second question is on the new launches. So, we had a lot of products for approval in India, especially on the onco [oncology] and the respiratory side. So, any update you want to share on the possible launches, if any, this year and next year?